Update on velaglucerase alfa(alize the Company's results could bemate...)

Date:9/8/2009

alize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

    For further information please contact:

    Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160
                       Eric Rojas (North America)         +1-617-551-9715
    Media              Jessica Mann (Rest of the World)   +44-1256-894-280
                       Jessica Cotrone (North America)    +1-617-613-4640

'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
2. ThromboGenics NV Announces Business Update and Half Year Results 2009
3. Wyeth Provides Regulatory Update on Prevnar 13* in the United States
4. ThermoGenesis Provides Update on Fiscal 2009 Results
5. ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12
6. GeoVax Labs, Inc. Provides Clinical Studies Update
7. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
8. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
9. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
10. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications